Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 8.39 as of 2026-10-06T15:12:39.106Z.
Consensus retrieved: 2026-10-06T12:46:23.709Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:12:39.106Z.
Quote observation: 2026-10-06T15:10:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 60c60f9730168f961ae5802b8b984853ffa10d75cec87ff2fe3ca57d1f3eaeef
Forward PE Ratio (8.39) = Dated Quote Price ($35.42) / Consensus Forward EPS ($4.22)
FORWARD PE RATIO
8.39
SECTOR MEDIAN · HEALTHCARE
19.19
median of 165 covered companies
CURRENT VS SECTOR MEDIAN
-56.28%
vs the sector median at left
Indivior Pharmaceuticals Inc
Market Cap
$4.42B
Forward PE Ratio
8.39
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Indivior Pharmaceuticals Inc (INDV) | $4.42B | 8.39 |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.45B | N/A |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.37B | N/A |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.36B | N/A |
| BillionToOne, Inc. (BLLN)vs › | $4.62B | 126.59 |
| Option Care Health, Inc. (OPCH)vs › | $4.64B | 16.49 |
| LifeStance Health Group, Inc. (LFST)vs › | $4.66B | 74.85 |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.69B | N/A |
| LivaNova PLC (LIVN)vs › | $4.12B | 17.22 |
| AbCellera Biologics Inc. (ABCL)vs › | $4.07B | N/A |
Trailing P/E
12.7
reported TTM EPS
Forward P/E
8.4
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $4.22 implies +51.3% EPS growth vs the reported trailing $2.79.
At the dated quote price of $35.42, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $4.22 | $4.18 – $4.25 | 2 | 8.4x |
| 2027-12-31 | $4.62 | $4.58 – $4.65 | 2 | 7.7x |
| 2028-12-31 | $4.84 | $4.32 – $5.36 | 2 | 7.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
